SCHEMBL4528026

SCHEMBL4528026

CC(C)(C)[Si](C)(C)OC1CCN(c2ncc(CC(C#N)C(=O)N(Cc3cccc(Cl)c3Cl)C3CC3)s2)C1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
REN P00797 9/20 0.36
SLC6A4 P31645 4/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A3 Q01959 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SCD O00767 1/20 0.32
GHSR Q92847 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522097 1.00 REN (0.36) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4525958 1.00 REN (0.36) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4525659 0.88 REN (0.47) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4525661 0.88 REN (0.47) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4529154 0.88 REN (0.47) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4105637 0.84 REN (0.42) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4520476 0.84 REN (0.42) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4105634 0.84 REN (0.42) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4523064 0.82 REN (0.36) RENSLC6A4SLC6A2SLC6A3CYP3A4
SCHEMBL4523060 0.82 REN (0.36) RENSLC6A4SLC6A2SLC6A3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088457-A1 Primary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS, LTD. (CH) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088457-A1 Primary Amines as Renin Inhibitors REN, ACE, AGTR1 REN 1/4885SLC6A4 413/4885SLC6A2 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.